Literature DB >> 31423066

Schimke Immuno-osseous Dysplasia: A Case Report.

Amir Hossein Babaei1, Soroor Inaloo2, Mitra Basiratnia3.   

Abstract

Schimke immuno-osseous dysplasia (SIOD) is a rare inherited disease characterized by steroid resistant nephrotic syndrome, spondyloepiphyseal dysplasia, and T-cell immunodeficiency. Focal segmental glomerulosclerosis (FSGS) is the most frequent renal pathological finding associated with proteinuria in SIOD. In this case report, we describe a 4.5-year-old boy who presented with nephrotic syndrome and ventricular septal defect followed by tremor in the limbs after-cerebral infarction. It is emphasized that SIOD should be considered in children with wide range of presentation, from growth retardation, steroid resistant nephrotic syndrome, and bone, cardiac, and neurological abnormalities in the late childhood or even adolescence.

Entities:  

Keywords:  Cardiovascular abnormalities; SMARCAL1; Schimke immuno osseous dysplasia; kidney diseases; tremor

Year:  2019        PMID: 31423066      PMCID: PMC6668313          DOI: 10.4103/ijn.IJN_95_18

Source DB:  PubMed          Journal:  Indian J Nephrol        ISSN: 0971-4065


Introduction

Schimke immuno-osseous dysplasia (SIOD) is a rare disease caused by a biallelic mutation in the SMARCAL1 gene. It is estimated that the incidence of SIOD is 1 in every 1,000,000 to 3,000,000 live births in the United States.[1] Typical clinical and laboratory findings in SIOD include steroid resistant nephrotic syndrome (SRNS), spondyloepiphyseal dysplasia, T-cell immunodeficiency, progressive renal failure, and hypothyroidism. Transient ischemic attacks, cerebral infarction, atherosclerosis, and migraine-like headache are common neurologic manifestations of SIOD.[234] In this article, we describe a 4.5-year-old boy who presented with nephrotic syndrome and other extra renal manifestations from Iran.

Case History

The proband was the second child of healthy consanguineous (3rd degree) parents. Both parents and siblings were healthy and had no developmental or growth disorders. The first pregnancy of his mother was a boy delivered by caesarean section because of oligohydramnios at gestational age of 31 weeks. He died 2 weeks after delivery because of a cardiac anomaly. The cause of death was probably valvular agenesis, but due to the dissatisfaction of parents, no further evaluation was done to understand the exact cause of his death. The proband was the product of premature delivery with the gestational age of 32 weeks through caesarean section because of intrauterine growth restriction and oligohydramnios (birth weight = 1670 gram, body length = 42 cm, and head circumferences = 32 cm). He was admitted 4 days in neonatal intensive care unit (NICU) because of prematurity and jaundice. In NICU, because of low O2 saturation and abnormal cardiac exam, echocardiography was done, and ventricular septal defect (VSD) and pulmonary hypertension were diagnosed. When he was 4 months old, serum insulin-like growth factor 1, growth hormone, and IGF binding protein level were below the normal range (40 ng/ml, 8.5 U/L, and 1068 ng/ml, respectively). Therefore, growth hormone therapy was started for him, but no response was observed according to his weight and length for age curves. He underwent VSD repairing surgery at the age of 4.5 months. At the age of 2 years, the brain MRI was done for better evaluation of the cause of his growth failure. It showed hypoplastic pituitary gland. There was no sign of brain infarction at this time. When he was 2.5 years old, in routine work up, proteinuria (3+ protein in a random urine sample and 1383 mg protein in the 24-h urine) and hypercholesterolemia (323 mg/dl) were detected, and prednisolone with atorvastatin were started for him with impression of nephrotic syndrome. Kidney biopsy was not done owing to lack of consent from his parents. His parents discontinued prednisolone at the age of 4 years. After 6 months, because of severe edema and exacerbation of nephrotic syndrome, he received rituximab in another center. After 4 days, he developed tremor in the upper and lower limbs (more significant in the right hand), fever, and mouth aphthous lesion and was admitted in our center. On physical exam, he had a triangular face, broad nasal bridge, low-set ears, frontal bossing, short trunk, and kyphosis (height = 76 cm, weight = 8.8 kg, and head circumference = 49 cm). In addition, syndactyly of the second and third toes of the left foot, Café au lait spot over the trunk and right undescended testis were detected [Figure 1]. Except for an increase in the cortical echogenicity of both kidneys, abdominal ultrasound did not reveal any other abnormalities. The dental age was delayed compared to chronological age. The bone survey showed delayed bone age, J-shaped sella, generalized osteopenia, shallow acetabulum on both sides without narrow pelvis, bilateral small femoral heads, and flattening of the cervical and thoracic vertebrae.
Figure 1

Anterior (a) and lateral (b) views of the patients show triangular face, broad nasal bridge, low-set ears, frontal bossing, short trunk, and kyphosis

Anterior (a) and lateral (b) views of the patients show triangular face, broad nasal bridge, low-set ears, frontal bossing, short trunk, and kyphosis ECG showed 1st degree AV block. Echocardiography showed trivial mitral regurgitation, mild tricuspid regurgitation, an ejection fraction of 77%, and medium to large perimembranous VSD (7.7 mm) associated with bidirectional shunt. Table 1 shows the laboratory findings in this admission. Urine culture showed growth of Escherichia coli. Further workups were not suggestive of endocarditis.
Table 1

Laboratory data of the patient on admission

Laboratory testsMeasured valuesNormal range
Hemoglobin (g/dl)10.912-14
White blood cells (103/μl)1.4004000-10000
Polymorph (%)80
Lymphocyte (%)10
Monocyte (%)10
Platelet (103/μl)342000150000-450000
Reticulocyte (%)1.80.5-1.5
Erythrocyte sedimentation rate (ESR) (mm/h)950-20
C-reactive protein (CRP) (mg/l)5.5Under 6
Blood urea nitrogen (BUN) (mg/dl)136-21
Creatinine (mg/dl)10.6-1.2
Alanine aminotransferase (unit/l)107-40
Aspartate aminotransferase (unit/l)2912-45
Alkaline phosphatase (unit/l)123180-420
Total bilirubin (mg/dl)0.50.2-1.2
Direct bilirubin (mg/dl)0.1Under 0.4
Albumin (g/dl)23.5-5.2
Sodium (meq/l)136136-145
Potassium (meq/l)3.93.5-5.5
Calcium (mg/dl)8.18.8-10.2
Phosphorus (mg/dl)3.82.7-4.5
Triglyceride (mg/dl)641Under 150
Cholesterol (mg/dl)293Under 200
Thyroid stimulating hormone (TSH) (mIu/ml)2.160.35-4.94
T4 (µg/dl)4.94.78-11.72
Free T4 (ng/dl)1.480.7-1.48
T3 (ng/dl)5658-159
Parathyroid hormone (pg/ml)20.115-68.3
Immunoglobulin G (g/l)4.1366.85-18.37
Immunoglobulin M (g/l)0.4790.4-1.8
Immunoglobulin A (g/l)1.0950.4-1.8
Dihydrorhodamine119Above 50
Total T-cell (CD3+) (%)2743-76
T helper cell (CD4+) (%)1923-48
T cytotoxic cell (CD8+) (%)814-33
Natural killer cell (CD16+) (%)734-23
B cell (CD19+) (%)014-44
Gated leukocytes (CD45+)79
(CD4+/CD8+)2.380.9-2.9
Natural killer cell (CD56+) (%)734-23
Monocyte (CD14+) (%)183-6
CD20+ (%)014-44
Adhesion molecules (CD11b)Normal
ANA (unit/ml)3Under 10
C-ANCA (unit/ml)0.5Under 12
P-ANCA (unit/ml)0.3Under 12
Anti-dsDNA (unit/ml)0.3Under 16
Urine analysisSpecific gravity: 1.010Protein: 3+Blood: 3+Glucose: 1+RBC: 2-4WBC: 1-2Bacteria: few
24-h urine protein (mg)1237Under 140
Laboratory data of the patient on admission Brain MRI revealed diffuse brain atrophy, periventricular banding and capping as well as pulvinar and bithalamic infarctions extending to the midbrain and infarction in the right inferior cerebellum. In addition, a lacunar infarction in the left side of the deep frontal white matter was seen, which was suggestive of arterial infarction. The brain magnetic resonance angiography (MRA) showed early beaded appearance and irregularity in the anterior cerebral artery and middle cerebral artery, which can be in favor of small vessel disease and mimics early stage of moyamoya [Figure 2].
Figure 2

Brain MRI revealed diffused brain atrophy and periventricular banding and multiple infarctions in the brain. The MRA showed early beaded appearance and irregularity in the anterior cerebral artery and middle cerebral artery

Brain MRI revealed diffused brain atrophy and periventricular banding and multiple infarctions in the brain. The MRA showed early beaded appearance and irregularity in the anterior cerebral artery and middle cerebral artery Because of the characteristic findings, a clinical impression of SIOD was considered, and analysis of SMARCAL1 gene for detection of mutation was performed. The result of the test showed a homozygous, non-synonymous mutation c.[1439C>T] that caused a missense mutation (p.P480L) in the SMARCAL1 protein. The mutation c.[1439C>T] was found by direct sequencing of both sense and antisense strands of the 16 coding and two non-coding exons of SMARCAL1. His parents were heterozygous carriers of the same mutation [Figure 3].
Figure 3

Analysis of SMARCAL1 gene revealed a homozygous, non-synonymous mutation c.[1439C>T]. (a) Proband, (b) Father, (c) Mother

Analysis of SMARCAL1 gene revealed a homozygous, non-synonymous mutation c.[1439C>T]. (a) Proband, (b) Father, (c) Mother His parents got discharged him from the hospital with their personal consent, and he died 1 month later. Informed consent form was obtained from parents for publishing the images and clinical data before participation in the study in accordance with the protocol approved by the ethics committee of Shiraz University of Medical Sciences.

Discussion and Conclusions

We present a 4.5-year-old boy with steroid resistant nephrotic syndrome; failure to thrive; and skeletal, cardiac, and neurological anomalies in favor of SIOD. The exact etiology of SIOD is unclear. Mutations of SMARCAL1 gene were detected in about 50% to 60% of patients with SIOD.[1] FSGS is the most frequent renal pathological finding associated with proteinuria in SIOD. FSGS in individuals with SIOD is usually identified between 1 and 14 years of age and leads to end-stage renal disease in short run.[5] Although FSGS is the leading cause of SRNS, minimal change disease, membranous nephropathy, and mesangial proliferative glomerulonephritis have also been described as the causes of SRNS. In these individuals, there is evidence of temporary reductions in proteinuria by using angiotensin-converting enzyme inhibitors, or cyclosporine-A.[1] Our patient was treated by steroid and rituximab as a case of idiopathic SRNS because the diagnosis of SIOD was not made at that time and after admission in our ward by impression of SIOD, steroid was tapered and he only received supportive therapy. Functional and anatomical cardiac problems are very uncommon in SIOD.[3] Up to now, VSD was reported only in a 16-year-old girl.[6] Fatty infiltration of the cardiac right ventricular wall was seen in another patient.[3] A prior study revealed the role of SMARCAL1 gene expression in the development of murine cardiomyocytes in the embryonic period.[7] As a result of recent advances in transplantation and dialysis, life expectancy in these children has increased. Subsequently, cerebrovascular disease has become an important cause of morbidity and mortality.[89] Neurologic presentations in SIOD result from several reasons. Hypertension and hyperlipidemia secondary to renal disease combined with immune dysfunction could predispose the patient to atherosclerosis.[10] Movement disorders such as limbs tremor are uncommon after stroke.[11] Tremor mostly develops after the infarction of the thalamus, especially the posterior nucleus of the thalamus.[12] Therefore, the presence of tremor, as a novel presentation of SIOD, following stroke can be explained. In conclusion, we reported a 4.5-year-old boy, a case of SIOD, who presented with nephrotic syndrome and suffered from cardiac problem and cerebral infarction. We emphasize that SIOD has a wide range of presentations, from SRNS to cardiac and neurologic abnormalities.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

This article was supported by the Vice Chancellor for Research of Shiraz University of Medical Sciences (grant number: 94-01-18-10110).

Conflicts of interest

There are no conflicts of interest.
  12 in total

1.  Tremor following ischemic stroke of the posterior thalamus.

Authors:  Dennis A Nowak; Birgit Seidel; Birgit Reiner
Journal:  J Neurol       Date:  2010-06-26       Impact factor: 4.849

2.  Schimke immuno-osseous dysplasia: a cell autonomous disorder?

Authors:  Leah I Elizondo; Cheng Huang; Jennifer L Northrop; Kimiko Deguchi; Johanna M Clewing; Dawna L Armstrong; Cornelius F Boerkoel
Journal:  Am J Med Genet A       Date:  2006-02-15       Impact factor: 2.802

3.  Schimke immune-osseous dysplasia: A case report.

Authors:  Ashraf Bakr; Riham Eid; Amr Sarhan; Ayman Hammad; Ahmed Mahmoud El-Refaey; Atef El-Mougy; Mohammed Magdy Zedan; Fatma ElHusseini
Journal:  Saudi J Kidney Dis Transpl       Date:  2015-09

4.  Internal carotid artery surgical revascularization in a pediatric patient with Schimke immuno-osseous dysplasia.

Authors:  Erick M Westbroek; Nitin Mukerji; Paul Kalanithi; Gary K Steinberg
Journal:  J Neurosurg Pediatr       Date:  2014-11-28       Impact factor: 2.375

5.  Schimke immuno-osseous dysplasia.

Authors:  Mitra Basiratnia; Mohammad H Fallahzadeh
Journal:  Saudi Med J       Date:  2007-03       Impact factor: 1.484

6.  Schimke immuno-osseous dysplasia: a clinicopathological correlation.

Authors:  J Marietta Clewing; Barbara C Antalfy; Thomas Lücke; Behzad Najafian; Katja M Marwedel; Akira Hori; Ralph M Powel; A F Safo Do; Lydia Najera; Karen SantaCruz; M John Hicks; Dawna L Armstrong; Corndins F Boerkoel
Journal:  J Med Genet       Date:  2006-07-13       Impact factor: 6.318

7.  Eltrombopag (thrombopoietin-receptor agonist) and plasmapheresis as rescue therapy of acute post-renal transplant immune thrombocytopenia in a child with Schimke immuno-osseous dysplasia-case report.

Authors:  Ryszard Grenda; Wioletta Jarmużek; Joanna Latoszyńska; Sylwester Prokurat; Jacek Rubik
Journal:  Pediatr Transplant       Date:  2016-09-26

8.  Rituximab resistant evans syndrome and autoimmunity in Schimke immuno-osseous dysplasia.

Authors:  Jakub Zieg; Anna Krepelova; Alireza Baradaran-Heravi; Elena Levtchenko; Encarna Guillén-Navarro; Miroslava Balascakova; Martina Sukova; Tomas Seeman; Jiri Dusek; Nadezda Simankova; Tomas Rosik; Sylva Skalova; Jan Lebl; Cornelius F Boerkoel
Journal:  Pediatr Rheumatol Online J       Date:  2011-09-13       Impact factor: 3.054

9.  Tremor onset with acute frontal infarct and disappearance with the second stroke.

Authors:  Deniz Yerdelen; Selin Yetkinel; Ali Dogan
Journal:  Neurosciences (Riyadh)       Date:  2015-04       Impact factor: 0.906

10.  A novel SMARCAL1 mutation associated with a mild phenotype of Schimke immuno-osseous dysplasia (SIOD).

Authors:  Luisa Santangelo; Maddalena Gigante; Giuseppe Stefano Netti; Sterpeta Diella; Flora Puteo; Vincenza Carbone; Giuseppe Grandaliano; Mario Giordano; Loreto Gesualdo
Journal:  BMC Nephrol       Date:  2014-03-03       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.